Glioblastoma multiforme (GBM) is a disease of the entire brain. Even complete surgical resection of the tumor-bearing hemisphere inevitably leads to recurrence and has been abandoned. Nonetheless, the majority of clinical trials employing small molecule drugs have focused their measurements of efficacy (both clinical outcome and biomarkers) on the bulk tumor mass that can be surgically removed. This is done in spite of mounting evidence that suggests the inevitable relapse and lethality of GBM is due to a failure to effectively target invasive glioma cells. Brain tumor cells overexpress protective active efflux transport systems, including p-glycoprotein (Pgp) and breast cancer resistance protein (BCRP). The blood-brain barrier (BBB) in the tumor core is """"""""leaky"""""""", allowing systemic drug delivery, but glioma cells infiltrate normal brain structures centimeters away from the margin of surgical resection where the BBB is intact and has functional efflux transport systems. Molecularly- targeted anti-tumor agents such as tyrosine kinase inhibitors (TKIs, e.g., imatinib, erlotinib, dasatinib) have their efficacy limited by sequential barriers to delivery to the actual target, including barriers to macroscopic distribution (active efflux at the BBB) and barriers to microscopic delivery (active efflux from invasive glioma cell). Therefore, drug delivery strategies that (1) improve the delivery of selected """"""""molecularly-targeted"""""""" chemotherapeutic agents through the BBB, and (2) improve the intracellular drug accumulation in invasive glioma cells, will significantly enhance the efficacy of molecularly-targeted therapy. Our central hypothesis is that invasive glioma cells can be targeted through specific inhibition of active efflux at the level of both the BBB and the invasive tumor cell leading to improved efficacy of molecularly-targeted tyrosine kinase inhibitors. We propose three specific aims to test this hypothesis.
Aim 1 will characterize strategies to improve TKI delivery and efficacy in both human and mouse primary glioma cell lines.
Aim 2 will determine the influence of active efflux, and optimize strategies to overcome efflux, on TKI efficacy in a novel spontaneous mouse model of glioma that grows invasively.
Aim 3 will determine the influence of inhibiting active efflux transport using a novel prodrug targeting Pgp and BCRP on the efficacy of TKIs in a primary human glioma xenograft model that grows invasively relative to traditional xenografts. Completion of these aims will indicate if active efflux transport at the BBB, the invasive glioma cell barrier, or both is an important mechanism that can influence the efficacy of molecularly-targeted therapy by limiting drug delivery to the invasive glioma cell. If successful, this information should be readily translatable to clinical trials and lead to eventual improvement in the treatment of gliomas, and other tumors of the central nervous system.

Public Health Relevance

Currently, there are no effective treatments for malignant brain tumors. This represents a significant unmet medical need, and if active drug efflux limits drug delivery to the brain leading to therapeutic failure, then improved delivery of an effective agent is possible through inhibiting drug efflux. Improving drug delivery could lead to improved patient outcomes, including longer progression free survival and possible cure.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Schools of Pharmacy
United States
Zip Code
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Laramy, Janice K; Kim, Minjee; Gupta, Shiv K et al. (2017) Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther 363:136-147
Klank, Rebecca L; Decker Grunke, Stacy A; Bangasser, Benjamin L et al. (2017) Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level. Cell Rep 18:23-31
Mittapalli, Rajendar K; Chung, Alexander H; Parrish, Karen E et al. (2016) ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model. Mol Cancer Ther 15:819-29
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Gampa, Gautham; Vaidhyanathan, Shruthi; Resman, Brynna-Wilken et al. (2016) Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep 2:309-325
Parrish, Karen E; Cen, Ling; Murray, James et al. (2015) Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 14:2735-43
Gummadi, Tulasi; Zhang, Ben Y; Valpione, Sara et al. (2015) Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res 25:75-9
Becker, Chani M; Oberoi, Rajneet K; McFarren, Stephan J et al. (2015) Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro Oncol 17:1210-9

Showing the most recent 10 out of 33 publications